CTRI/2021/07/035264尚未招募未知
An open-label, multicenter, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, two-way crossover, comparative oral bioavailability study of Temozolomide 30 mg/ml Oral Suspension of Shilpa Medicare Limited, India with Temodal® (Temozolomide) 250 mg Hard Capsules of Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands, in adult human patients with Glioblastoma Multiforme or Anaplastic Astrocytoma under fasting condition.
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •i.Willing and able to provide written informed consent prior to any study-related activities being performed and to follow protocol requirements.
- •ii.Patients aged 18 to 65 years (both inclusive) having body mass index (BMI) at least 17.00 calculated as weight in kg/height in m².
- •iii.Patients with Glioblastoma Multiforme or Anaplastic Astrocytoma, who are eligible for Temozolomide 150 mg/m² once daily as their calculated individualized maintenance dose for 5 consecutive days.
- •iv.Able to swallow and retain oral medications.
- •v.Non-smokers and non-alcoholics.
- •vi.Eastern Cooperative Oncology Group (ECOG) performance status <= 2.
- •vii.Life expectancy of at least 3 months.
- •viii.Acceptable hematology status:
- •a) Hemoglobin >= 9 g/dL.
- •b) Absolute neutrophil count (ANC) >= 1500 cells/µL.
- •c) Platelet count >= 1,00,000 cells/µL.
- •ix.Patients with acceptable renal and hepatic function.
- •x.Male patients must agree to use an effective method of contraception during study and for at least 6 months after receiving the last dose and must seek advice on cryoconservation of sperm prior to treatment.
- •xi.Women of childbearing potential, (defined as women physiologically capable of becoming pregnant, unless they are using effective method of contraception during dosing of the IP) practicing any acceptable methods of contraception Acceptable methods of contraception are:
- •a.Oral or parenteral (injection), patch or implant hormonal contraception which has been used continuously for at least one month prior to the first dose of study medication.
- •b.Intrauterine device or intrauterine system.
- •c.Double barrier method of contraception (condom and occlusive cap or condom and spermicidal agent).
- •d.Male sterilization (at least 6 months prior to the screening, should be the sole male partner for that patient.
- •e.Female sterilization (surgical bilateral oophorectomy) or tubal ligation within at least 6 weeks prior to study participation.
- •f. Total abstinence, partial abstinence is not acceptable.
- •xii.Female patients with negative serum pregnancy test at screening.
- •xiii.No history of addiction to any recreational drug or drug dependence or alcohol addiction.
排除标准
- •i.Hypersensitivity or intolerance to temozolomide, dacarbazine (DTIC), ondansetron or to any of the excipients of investigational product.
- •ii.Patients with severe myelosuppression.
- •iii.Pregnant or lactating women.
- •iv.Major surgical procedure (including periodontal) within 28 days of first dose of investigational product.
- •v.Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption.
- •vi.Patients taking or scheduled to receive any prohibited medications such as Dacarbazine (DTIC), Valproic Acid and Myelosuppressive Agents during the study participation.
- •vii.Surgical or other non-healing wounds.
- •viii.History of other malignancies in the last 5 years. Potential patients with prior history of in situ cancer or basal or squamous cell skin cancer are eligible.
- •ix.Has not recovered to Grade 0 or 1 toxicity from previous anticancer treatments or previous investigational agents. Exceptions are alopecia (any grade is acceptable), Hemoglobin >= 9 g/dL, fatigue (Grade 2 is acceptable), and peripheral neuropathy (stable Grade 2 is acceptable), (Per National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], V5.0).
- •x.History or presence of any uncontrolled systemic disease (e.g. cardiovascular disease,hypertension, diabetes mellitus etc.).
- •xi.Any other medical condition or serious intercurrent illness that, in the opinion of the investigator may make it undesirable for the patient to participate in the study, but not limited to cirrhosis or psychiatric illness/social situations that would limit adherence to study requirements.
- •xii.Participation in any clinical study within 90 days before the first dose of investigational product.
- •xiii.Loss of >= 350mL blood within 90 days before the first dose of investigational product.
- •xiv.Patients with positive serology for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or Human Immunodeficiency Virus (HIV).
- •xv.Patient with coronavirus infection (COVID-19).
研究者
相似试验
暂停
不适用
Bioavailability study of Sunitinib Capsules 50mg of with SUTENT® (Sunitinib Malate) Capsules 50mg in adult human patients with Gastrointestinal Stromal Tumors (GIST) or Advanced Renal Cell Carcinoma (RCC) under fed conditionsCTRI/2021/04/033234Shilpa Medicare Limited
已完成
不适用
Bioequivalence study of Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) in ovarian cancer subjects whose disease has progressed or recurred after platinum-based chemotherapy under standard diet (non-high-fat) conditions Subjects.CTRI/2022/12/048463Alembic Pharmaceuticals Limited68
招募中
Unknown
To measure the amount and the rate at which olaparib is absorbed from the olaparib 150 mg tablets and becomes available in body of cancer patients (ovarian cancer or breast cancer or pancreatic adenocarcinoma or prostate cancer).CTRI/2024/04/065314Sun Pharmaceutical Industries Limited
尚未招募
不适用
Steady-state Bioequivalence Study of Clozapine Tablets USP 100mg among Subjects with Schizophrenia in Fasting ConditioCTRI/2016/06/007015Micro Labs Limited India12
招募中
Unknown
Pharmacokinetic Study of Pazopanib in Advanced Renal Cell Carcinoma patientsCTRI/2023/09/057633MSN Laboratories Private Limited